Pharmaceutical composition for treating drug-resistant tuberculosis

Abstract

The invention relates to an artemisinin pharmaceutical composition, and particularly relates to a composition of nano chitosan artemisinin and antituberculosis drugs, used for treating drug-resistant tuberculosis. The pharmaceutical composition comprises the following effective components: the antituberculosis drugs, the nano chitosan artemisinin, three nano chitosan artemisinin derivatives or artemisinin and a derivative of artemisinin, wherein the nano chitosan artemisinin is prepared from the following ingredients by weight percent: 40-805 of artemisinin or artemisinin derivatives, 1-5% of polyvinyl pyrrolidone and 15-50% of nano chitosan. Artemisinin drugs, the nano chitosan artemisinin and derivatives, and the antituberculosis drugs are used as the pharmaceutical composition, so that drug-resistant tubercle bacillus can be inhibited and killed; and the pharmaceutical composition has a prominent curative effect on the drug-resistant tuberculosis.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating drug-resistant tuberculosis, in particular to a composition of artemisinin drugs and nano artemisinin and anti-tuberculosis drugs. Background technique [0002] In recent years, the incidence of tuberculosis has gradually increased and has become a major global public health problem. The increase in the infection rate of drug-resistant tuberculosis is an important factor causing the sharp rise of tuberculosis, and it also has a serious impact on the control of tuberculosis. According to the World Health Organization (WHO), about 2 billion people worldwide are infected with Mycobacterium tuberculosis. Although new cases of tuberculosis have declined between 2010 and 2011, tuberculosis is still a major cause of death from infectious diseases. Despite the large-scale use of BCG vaccination and anti-tuberculosis drugs, the infection rate of tuberculosis is still high, and the increase of dr...

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to overcome the limited types and quantities of existing anti-tuberculosis drugs, and to provide a drug-resistant tuberculosis drug-resistant tuberculosis treatment effect is poor, or even ineffective.

Images